3 days Ago
DNY59/E+ via Getty Images Kairos Pharma ( NYSEMKT: KAPA ) priced on Monday its initial public offering of 1.5M shares of common stock at a public offering price of $4 per share. The gross proceeds from the offering are expected to be $6.
2M. Kairos Pharma ( KAPA ) intends to use the net proceeds from the offering to fund its Phase 1 trial in lung cancer and Phase 2 trial in prostate cancer for its lead product candidate ENV 105. The company’s common stock has been approved for listing on the NYSE American and trading is expected to begin on September 16, 2024 under the symbol “KAPA.
” More on Kairos Pharma, Ltd. IPO Roundup: Bicara Therapeutics, Kairos Pharma and more Financial information for Kairos Pharma, Ltd..
